Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $56.00.

Several research firms have recently weighed in on AGIO. Weiss Ratings reiterated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research note on Saturday, September 27th. HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Scotiabank cut their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. Finally, Bank of America cut their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $40.89 on Tuesday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of 3.72 and a beta of 0.83. Agios Pharmaceuticals has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a fifty day moving average of $37.51 and a 200-day moving average of $33.91.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Equities analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,651 shares of the firm’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer owned 33,870 shares in the company, valued at $1,245,399.90. This trade represents a 9.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sarah Gheuens sold 11,914 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares of the company’s stock, valued at approximately $2,327,685.29. This represents a 16.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,596 shares of company stock worth $1,364,438 over the last quarter. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently modified their holdings of the business. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $40,000. CWM LLC boosted its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 499 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at about $133,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.